IP Library Granted Patent US 11,246,842
Granted Patent B2
US 11,246,842 · App. 14/975,695 · Granted Feb 15, 2022

Method and compositions for dissolving or solubilizing therapeutic agents

Inventors: Adam R. Standley (Cambridge, MA); Kaliappanadar Nellaiappan (Lexington, MA); Brent A. Buchine (Watertown, MA)
Assignee: Windgap Medical, Inc.
A61K31/137A61K9/0019A61K9/143A61K9/145A61K9/1617A61K9/1676A61K31/4045A61K31/485A61K38/26A61M5/3294A61M5/284
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,246,842
App. No.
14/975,695
Granted
Feb 15, 2022
Kind
B2
Abstract

The invention provides pharmaceutical compositions comprising a dry medicament. The dry medicaments can be rapidly dissolved, solubilized, and/or reconstituted to deliver to a subject. The present invention provides methods of preparing a medical solution. The medical solution can be prepared from mixing the pharmaceutical composition as described herein with a first liquid.

Claims (21)

1. An autoinjector comprising a dry pharmaceutical composition that comprises a mixture of a therapeutically effective amount of a dry epinephrine and one or more dry pH adjusting agents, wherein the dry epinephrine and one or more dry pH adjusting agents are located in a first chamber of the autoinjector, wherein the autoinjector comprises a second chamber comprising a first liquid, and wherein the first liquid is an acid aqueous solution having a pH from 0.1 to 6.0, wherein the dry epinephrine and the one or more dry pH adjusting agents are in different particles, and wherein the dry epinephrine particles dissolve faster than the one or more dry pH adjusting agent particles when mixed with the first liquid.

2. The autoinjector of claim 1 , wherein the dry epinephrine is more soluble in the acid than the one or more dry pH adjusting agents.

3. The autoinjector of claim 1 , wherein the dry epinephrine is in particles that are smaller than the one or more dry pH adjusting agents.

4. The autoinjector of claim 3 , wherein the dry epinephrine particles have a size between about 1 μm and about 30 μm.

5. The autoinjector of claim 3 , wherein the one or more dry pH adjusting agent particles have a size between about 35 μm and about 100 μm.

6. The autoinjector of claim 1 , wherein the one or more dry pH adjusting agents are coated with one or more layers of a pharmaceutically acceptable carrier or one or more layers of a pharmaceutically acceptable polymer.

7. The autoinjector of claim 1 , wherein the first liquid is an acid, and the acid is HCl, phosphoric acid, or sulfuric acid.

8. The autoinjector of claim 1 , wherein the dry epinephrine is soluble at pH of about 0.5 to 6.9.

9. The autoinjector of claim 1 , wherein the one or more dry pH adjusting agents are selected from the group consisting of sodium and potassium buffering agents.

10. The autoinjector of claim 1 , wherein the dry epinephrine is epinephrine of a free base form.

11. The autoinjector of claim 1 , wherein the one or more dry pH adjusting agents comprise sodium citrate.

12. The autoinjector of claim 1 , wherein the dry epinephrine is between 5 to 10% by weight of the dry pharmaceutical composition and the one or more dry pH adjusting agents are between 90 to 95% by weight of the dry pharmaceutical composition.

13. The autoinjector of claim 1 , wherein the acid comprises HCl at a pH of between 0.5 and 2.0.

14. The autoinjector of claim 1 , wherein the composition is an amorphous solid or a porous matrix.

15. A method of preparing an epinephrine solution comprising mixing the dry pharmaceutical composition and the first liquid within the autoinjector of claim 1 .

16. The method of claim 15 , wherein the first liquid is sterile.

17. The method of claim 15 , wherein the first liquid comprises one solvent.

18. The method of claim 17 , wherein the first liquid comprises water.

19. The method of claim 15 , wherein the pH adjusting agent is sodium citrate, sodium acetate, potassium citrate, or potassium acetate.

20. The method of claim 15 , wherein the first liquid comprises water and an acid.

21. The method of claim 15 , wherein the dry epinephrine forms a readily solubilized salt upon being mixed with the first liquid.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2025
From: WINDGAP MEDICAL, INC.
To: WINDGAPLEGACYCO, LLC
Reel/Frame 071907/0607 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2016
From: STANDLEY, ADAM R.; NELLAIAPPAN, KALIAPPANADAR; BUCHINE, BRENT A.
To: WINDGAP MEDICAL, INC.
Reel/Frame 038737/0413 →
Continuity (2)
Provisional Application 62094063 · Dec 18, 2014
Related Publication 20160243060A1 · Aug 25, 2016
Cited By (1)
US 12,239,823